Renal failure is common in the United States with an estimated prevalence of 660,000 treated end-stage renal disease patients in 2015 [1]. Causes of renal failure are many, and complications from renal failure, underlying disease, and treatment are not infrequent. Examples of common skin manifestations include xerosis, pigmentary change, and nail dystrophies. Frequent disease-specific skin changes may be helpful in the diagnosis of primary disorders leading to renal disease or severity of disease including bullosis diabeticorum, sclerodactyly, or leukoctoclastic vasculitis. Some cutaneous changes, such as the multiple angiokeratomas of Fabry disease or the plexiform neurofibromas of neurofibromatosis, are pathognomonic of genetic disorders, which often lead to renal failure. Careful examination of the skin can provide crucial clues to diagnosis of renal failure causation and aid in monitoring complications.

1.
US Renal data System (USRDS): 2015 Annual Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007. http://www.usrds.org/2015/view/Default.aspx (accessed August 29, 2017).
2.
Pico MR, Lugo-Somolinos A, Sanchez JL, Burgos-Caldfron R: Cutaneous alterations in patients with chronic renal failure. Int J Dermatol 1992; 31: 860–863.
3.
Lupi O, Rezende L, Zangrando M, Sessim M, Silveira CB, Sepulcri MA, Duarte DJ, Cardim P, Fernandes MM, Santos Oda R: Cutaneous manifestations in end-stage renal disease. An Bras Dermatol 2011; 86: 319–326.
4.
Udayakumar P, Balasubramanian S, Ramalingam KS, Lakshmi C, Srinivas CR, Mathew AC: Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Indian J Dermaol Venerol Leprol 2006; 72: 119–125.
5.
Abdelbaqi-Salhab M, Shalhub S, Morgan MB: A current review of the cutaneous manifestations of renal disease. J Cutan Pathol 2003; 30: 527–538.
6.
Lindsay PG: The half-and-half nail. Arch Intern Med 1967; 119: 583–587.
7.
Brewster UC: Dermatologic manifestations of end-stage renal disease. Hosp Phys 2006; 42: 31–35.
8.
Mettang T, Kremer AE: Uremic pruritus. Kid Int 2015; 87: 685–691.
9.
Berger TG, Steinhoff M: Pruritus and renal failure. Semin Cutan Med Surg 2011; 30: 99–100.
10.
Duff M, Demidova O, Blackburn S, Shubrook J: Cutaneous manifestations of diabetes mellitus. Clin Diabetes 2015; 33: 40–48.
11.
McGeorge S, Walton S: Diabetic dermopathy. Br J Diabetes Vasc Dis 2014; 14: 94–97.
12.
Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A: Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 2013; 69: 783–791.
13.
Martin C, Requena L, Manrique K, Manzarbeitia FD, Rovira A; Sclerema diabeticorum in a patient with type 2 diabetes mellitus. Case Rep Endocrin 2013; 2013: 943798.
14.
Lipsky BA, Baker PD, Ahroni JH: Diabetic bullae: 12 cases of a purportedly rare cutaneous disorder. Int J Dermatol 2000; 39: 196–200.
15.
Pascoe VL, Fenves AZ, Wofford J, Jackson JM, Menter A, Kimball AB: The spectrum of nephrolcutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. J Am Acad Dermatol 2016; 74: 247–270.
16.
Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP: Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779–786.
17.
Ratzinger G, Zankl J, Eisendle K, Zelger B: Eosinophilic leukocytoclastic vasculitis – a spectrum ranging from Wells’ syndrome to Churg-Strauss syndrome? Eur J Dermatol 2014; 24: 603–610.
18.
Pakula AS, Garden JM, Roth SI: Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection. J Am Acad Dermatol 1993; 28: 850–853.
19.
Davin JC: Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 2011; 6: 679–689.
20.
Chasset F, Frances C: Cutaneous manifestations of medium- and large-vessel vasculitis. Clin Rev Allergy Immunol 2017; 53: 452–468.
21.
Luna PC, Boggio P, Larralde M: Dermatologic aspects of Fabry disease. J Inborn Errors Metab Screen 2016; 4: 1–7.
22.
Knoers NV, Bongers EM, van Beersum SE, Lommen EJ, van Bokhoven H, Hol FA: Nail-patella syndrome: identification of mutations in the LMX1B gene in Dutch families. J Am Soc Nephrol 2000; 11: 1762–1766.
23.
Han M, Criado E: Renal artery stenosis and aneurysms associated with neurofibromatosis. J Vasc Surg 2005; 41: 539–543.
24.
Lore F, Talidis F, Di Cairano G, Renieri A: Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. J Int Med 2001; 250: 37–42.
25.
Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681–1691.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.